C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give C4 Therapeutics a consensus "Moderate Buy" (five buys, one hold, one sell) with an average 12‑month target price of $7.75.
• C4 beat the latest quarter (EPS $(0.18) vs. $(0.43) est.; revenue $11.02M vs. $4.48M) but remains unprofitable with a negative ROE and wide negative net margin.
• Large investors have been increasing exposure—RA Capital, Bain Capital, Wells Fargo and Jane Street among them—leaving about 78.81% of the company owned by institutions.

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $7.75.

A number of research analysts have weighed in on the company. raised their price target on C4 Therapeutics from $20.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of C4 Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded C4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, February 28th. TD Cowen restated a "buy" rating on shares of C4 Therapeutics in a research note on Thursday, February 26th. Finally, Barclays raised their price target on C4 Therapeutics from $5.00 to $7.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CCCC. RA Capital Management L.P. acquired a new stake in shares of C4 Therapeutics in the fourth quarter valued at approximately $15,280,000. Bain Capital Life Sciences Investors LLC lifted its position in shares of C4 Therapeutics by 545.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,171,910 shares of the company's stock valued at $13,698,000 after buying an additional 6,060,000 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of C4 Therapeutics by 4,236.9% in the fourth quarter. Wells Fargo & Company MN now owns 809,260 shares of the company's stock valued at $1,546,000 after buying an additional 790,600 shares during the last quarter. Wasatch Advisors LP lifted its position in shares of C4 Therapeutics by 10.4% in the second quarter. Wasatch Advisors LP now owns 7,424,662 shares of the company's stock valued at $10,617,000 after buying an additional 700,253 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of C4 Therapeutics by 329.7% in the fourth quarter. Jane Street Group LLC now owns 874,794 shares of the company's stock valued at $1,671,000 after buying an additional 671,226 shares during the last quarter. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $2.90 on Friday. The company has a market cap of $282.98 million, a PE ratio of -2.13 and a beta of 2.85. C4 Therapeutics has a 52-week low of $1.09 and a 52-week high of $3.82. The stock has a 50-day simple moving average of $2.58 and a 200 day simple moving average of $2.39.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.25. The business had revenue of $11.02 million during the quarter, compared to the consensus estimate of $4.48 million. C4 Therapeutics had a negative return on equity of 53.83% and a negative net margin of 292.08%. On average, research analysts predict that C4 Therapeutics will post -1.52 earnings per share for the current fiscal year.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.